Why It Matters
As healthcare costs continue to rise, understanding how insurers can use AI to shift focus from expensive chronic treatment to prevention is critical for patients, providers, and policymakers. This episode offers timely insights into scalable strategies that could reshape affordability and improve health outcomes worldwide.
Key Takeaways
- •Cigna uses biosimilars to cut prescription drug costs dramatically.
- •Personalized care delivered via virtual, home infusion, and AI tools.
- •Partnerships with providers improve outcomes and reduce administrative friction.
- •Prior authorization reforms aim to streamline approvals and enhance transparency.
- •Future vision: trusted advisor offering integrated pricing, clinical navigation, technology.
Pulse Analysis
Cigna’s leadership acknowledges that soaring prescription drug prices are the top affordability challenge in U.S. healthcare. By accelerating the adoption of biosimilars and generics—evidenced by a $0 out‑of‑pocket Humira biosimilar that saved members $200 million—Cigna demonstrates how competitive pricing can curb spending while preserving innovative treatments. This strategy aligns with broader industry trends toward cost‑effective drug sourcing and highlights the insurer’s role in translating pharmaceutical breakthroughs into real‑world savings.
The conversation also spotlights Cigna’s push toward personalized, technology‑driven care. Leveraging AI‑powered virtual assistants, robust mobile apps, and a growing network of home‑infusion nurses, the company tailors services to individual preferences—whether patients favor telehealth, in‑home treatment, or traditional office visits. Advanced analytics enable precise sub‑segmentation, delivering the right information at the right moment, from elective surgery planning to chronic disease management, thereby improving outcomes and consumer satisfaction.
Finally, Cigna frames its future as a trusted advisor rather than a mere financing vehicle. By deep‑listening to members, providers, and employers, the insurer is reshaping prior‑authorization processes, fostering transparent partnerships with hospitals and physician groups, and expanding clinical navigation resources. The “Commitments to Better” initiative underscores a broader industry call for collaborative, patient‑centric solutions. In five years, Cigna aims to be known for integrated pricing, clinical expertise, and seamless digital experiences that meet rising consumer expectations and set a new standard for health‑insurer trust.
Episode Description
Health insurers are facing urgent challenges related to affordability, access, and how to safely and effectively leverage AI and emerging technologies. In this episode, McKinsey senior partner Celia Huber is joined by Brian Evanko, president and chief operating officer of The Cigna Group. In this role, Brian oversees all of the company's business units, including its two growth platforms: Cigna Healthcare, a health benefits business, and Evernorth, a health services business. Together, these business units serve customers in more than 30 countries.
From here, Brian has a unique view of the challenges facing the industry and the people it serves—including the fact that the vast amount of US healthcare spending goes toward chronic care. In their conversation, Brian shares his perspective on the innovation needed, such as through the adoption of AI, to improve affordability and support prevention.
Related Insights
Future of US healthcare: Gathering storm 2.0 or a golden age?
Tackling healthcare’s biggest burdens with generative AI
The race to create a vaccine: A conversation with Frank D’Amelio
Support the show: https://www.linkedin.com/showcase/mckinsey-strategy-&-corporate-finance/
See www.mckinsey.com/privacy-policy for privacy information
Show Notes
0
Comments
Want to join the conversation?
Loading comments...